Vertex could snag 250 more Kalydeco patients with EMA nod

Carly Helfand

Back in February, the FDA green-lighted  to treat cystic fibrosis in with one of 8 distinct gating mutations, dramatically swelling the orphan drug's patient pool.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS